Perrigo Company PLC (PRGO) Receives $88.40 Average PT from Brokerages
Perrigo Company PLC (NYSE:PRGO) has received an average rating of “Hold” from the nineteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, ten have assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $88.40.
PRGO has been the subject of several research reports. Cantor Fitzgerald reaffirmed a “buy” rating and set a $107.00 price target on shares of Perrigo in a research report on Wednesday, July 18th. ValuEngine raised shares of Perrigo from a “strong sell” rating to a “sell” rating in a research report on Monday, August 20th. Morgan Stanley reaffirmed an “equal weight” rating and set a $85.00 price target on shares of Perrigo in a research report on Monday, June 18th. Barclays lowered shares of Perrigo from an “overweight” rating to an “equal weight” rating and set a $110.00 price target for the company. in a research report on Wednesday, June 6th. Finally, Wells Fargo & Co reduced their price target on shares of Perrigo from $84.00 to $77.00 and set a “market perform” rating for the company in a research report on Tuesday, August 21st.
Shares of NYSE:PRGO opened at $72.57 on Friday. Perrigo has a fifty-two week low of $67.53 and a fifty-two week high of $95.93. The company has a quick ratio of 1.23, a current ratio of 1.81 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $10.08 billion, a price-to-earnings ratio of 14.31, a price-to-earnings-growth ratio of 2.39 and a beta of 0.83.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 18th. Investors of record on Friday, August 31st will be paid a dividend of $0.19 per share. The ex-dividend date is Thursday, August 30th. This represents a $0.76 dividend on an annualized basis and a dividend yield of 1.05%. Perrigo’s dividend payout ratio (DPR) is presently 15.42%.
In related news, EVP Svend Andersen acquired 7,200 shares of the business’s stock in a transaction that occurred on Tuesday, August 14th. The stock was bought at an average cost of $69.43 per share, for a total transaction of $499,896.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 6.90% of the company’s stock.
Several large investors have recently made changes to their positions in PRGO. FMR LLC grew its stake in shares of Perrigo by 1,200.9% during the 2nd quarter. FMR LLC now owns 5,170,125 shares of the company’s stock valued at $376,954,000 after acquiring an additional 4,772,696 shares during the period. Ceredex Value Advisors LLC bought a new position in shares of Perrigo during the 1st quarter valued at approximately $81,786,000. Renaissance Technologies LLC grew its stake in shares of Perrigo by 772.9% during the 2nd quarter. Renaissance Technologies LLC now owns 697,508 shares of the company’s stock valued at $50,855,000 after acquiring an additional 617,600 shares during the period. Starboard Value LP grew its stake in shares of Perrigo by 4.1% during the 2nd quarter. Starboard Value LP now owns 10,041,425 shares of the company’s stock valued at $732,120,000 after acquiring an additional 400,000 shares during the period. Finally, Los Angeles Capital Management & Equity Research Inc. grew its stake in shares of Perrigo by 156.6% during the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 574,392 shares of the company’s stock valued at $41,879,000 after acquiring an additional 350,539 shares during the period. Institutional investors own 82.01% of the company’s stock.
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.
Further Reading: Diversification in Investing
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.